Thursday, December 08, 2022 11:21:10 AM
Recent Trades - Last 10 of 1063
Time ET Ex Price Change Volume
11:02:31 Q 9.50 0.25 5
11:02:31 Q 9.50 0.25 200
11:02:30 Q 9.49 0.24 9
11:02:23 Q 9.49 0.24 75
11:02:23 Q 9.49 0.24 25
11:02:23 Q 9.49 0.24 100
11:02:14 Q 9.495 0.245 100
11:01:23 Q 9.5011 0.2511 100
11:00:52 Q 9.50 0.25 18
11:00:38 Q 9.50 0.25 39
Time ET Ex Price Change Volume
11:02:31 Q 9.50 0.25 5
11:02:31 Q 9.50 0.25 200
11:02:30 Q 9.49 0.24 9
11:02:23 Q 9.49 0.24 75
11:02:23 Q 9.49 0.24 25
11:02:23 Q 9.49 0.24 100
11:02:14 Q 9.495 0.245 100
11:01:23 Q 9.5011 0.2511 100
11:00:52 Q 9.50 0.25 18
11:00:38 Q 9.50 0.25 39
Bullish
History.htm
Recent BBIO News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:30:36 PM
- Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54 • GlobeNewswire Inc. • 03/30/2026 07:30:00 PM
- BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:33:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:32:18 PM
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/20/2026 08:01:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/13/2026 08:22:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/12/2026 08:15:36 PM
- BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 • GlobeNewswire Inc. • 03/11/2026 06:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/10/2026 08:02:29 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 09:17:48 PM
- BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference • GlobeNewswire Inc. • 03/04/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/24/2026 09:04:13 PM
- BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates • GlobeNewswire Inc. • 02/24/2026 09:01:00 PM
- BridgeBio to Participate in March Investor Conferences • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 11:39:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 11:36:26 PM
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/17/2026 11:22:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/17/2026 09:06:56 PM
- BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET • GlobeNewswire Inc. • 02/17/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 09:05:57 PM
- BioMarin, Ascendis slide as BridgeBio shakes up achondroplasia landscape • IH Market News • 02/12/2026 03:25:26 PM
- BridgeBio rallies on strong Phase 3 data for achondroplasia pill • IH Market News • 02/12/2026 03:22:41 PM
- BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia • GlobeNewswire Inc. • 02/12/2026 12:30:00 PM
